Nuvation Bio INC Form 4 insider transactions

Nuvation Bio's Chief Medical Officer, Liu Dongfang, executed pre-planned option exercises and subsequent sales of Class A Common Stock in November 2025.

Nuvation Bio's Chief Scientific Officer, Gary Hattersley, exercised stock options and subsequently sold 100,000 Class A Common Stock shares as part of a pre-arranged 10b5-1 plan.

Nuvation Bio Inc. Director and 10% owner Robert Mashal transferred 350,001 vested stock options to an irrevocable trust.

Nuvation Bio Inc.'s President and CEO, David Hung, has acquired 500,000 shares of Class A Common Stock, increasing his direct beneficial ownership to over 59 million shares.

Nuvation Bio Inc.'s Chief People Officer, Stacy Markel, has filed a Form 4 indicating a planned purchase of 10,000 shares of Class A Common Stock at $1.71 per share on June 18, 2025, under a Rule 10b5-1 trading plan.

Nuvation Bio Inc.'s Chief Financial Officer, Philippe Sauvage, has increased his direct ownership in the company through two open-market purchases of Class A Common Stock on June 16 and June 17, 2025.

Nuvation Bio Inc.'s Chief Commercial Officer, Colleen Sjogren, has increased her direct ownership in the company by purchasing 50,000 shares of Class A Common Stock.

Nuvation Bio Inc.'s Chief Regulatory Officer, Kerry Wentworth, has acquired 50,000 shares of Class A Common Stock through two open market purchases, signaling increased insider confidence.

Nuvation Bio Inc. Director Kathryn Falberg was granted 292,983 stock options with an exercise price of $2.03, aligning her interests with the company's long-term performance.

Nuvation Bio Inc. Director Kim D. Blickenstaff was granted 292,983 stock options with an exercise price of $2.03, aligning executive incentives with shareholder value.

Nuvation Bio Inc. Director William Anthony Vernon was granted 292,983 stock options with an exercise price of $2.03 per share, set to vest on the earlier of May 21, 2025, or the next shareholder annual meeting.

Nuvation Bio Inc. Director and 10% owner Robert Mashal was granted 292,983 stock options with an exercise price of $2.03, vesting on the earlier of May 21, 2025, or the next shareholder annual meeting.

Nuvation Bio Inc. Director Robert Bazemore was granted 292,983 stock options with an exercise price of $2.03, aligning his interests with the company's long-term performance.

Chief Medical Officer Dongfang Liu of Nuvation Bio Inc. reports the acquisition and disposal of Class A Common Stock on May 2, 2025, according to a Form 4 filing with the SEC.

Nuvation Bio's CEO, David Hung, recently acquired 500,000 shares of Class A Common Stock, signaling a strong commitment to the company's future.

Robert Mashal, a director at Nuvation Bio Inc., reported purchasing shares of Class A Common Stock through a trust.

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., acquired 500,000 stock options on February 28, 2025, according to a Form 4 filing with the SEC.

Colleen Sjogren, Chief Commercial Officer of Nuvation Bio Inc., reports the acquisition of 3,000 shares and a grant of stock options for 500,000 shares.

Philippe Sauvage, CFO of Nuvation Bio Inc., was granted 500,000 stock options on February 28, 2025.

Stacy Markel, Chief People Officer of Nuvation Bio Inc., reports the acquisition of stock options and shares, including those acquired through the Employee Stock Purchase Plan.

Moses Makunje, VP of Finance at Nuvation Bio, reports the acquisition of stock options and shares, including those from the Employee Stock Purchase Plan.

Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc., reports acquisition of shares and stock options.

Nuvation Bio Inc.'s CEO, David Hung, reports the acquisition of 2,000,000 stock options with an exercise price of $1.97, vesting over four years.

Gary Hattersley, Chief Scientific Officer of Nuvation Bio Inc., was granted stock options to purchase 500,000 shares of Class A Common Stock.

David C. Hanley, Chief Technical Operations Officer at Nuvation Bio, reports acquisition of shares and stock options.

A Nuvation Bio Inc. director, Junyuan Jerry Wang, sold 56,361 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Director Robert Mashal increases his stake in Nuvation Bio through trust purchases of Class A Common Stock.

Philippe Sauvage, CFO of Nuvation Bio Inc., was granted 750,000 stock options on October 7, 2024, according to a Form 4 filing with the SEC.

Director Anthony Vernon acquired 200,801 stock options in Nuvation Bio Inc. on September 3, 2024.

Kathryn E. Falberg, a director of Nuvation Bio Inc., reported the acquisition of stock options for 200,801 shares on September 3, 2024.